Skip to main content

Long-term treatment with arsenite activates HER1 and HER2 through upregulating EGF, TGFα, and HSP90 in a human uroepithelial cell line

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2

References

  1. Aballay LR, Diaz Mdel P, Francisca FM, Munoz SE. Cancer incidence and pattern of arsenic concentration in drinking water wells in Cordoba, Argentina. Int J Environ Health Res. 2012;22(3):220–31. https://doi.org/10.1080/09603123.2011.628792.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  2. Appert-Collin A, Hubert P, Cremel G, Bennasroune A. Role of ErbB receptors in cancer cell migration and invasion. Front Pharmacol. 2015;6:283. https://doi.org/10.3389/fphar.2015.00283.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  3. Bertelsen V, Stang E. The mysterious ways of ErbB2/HER2 trafficking. Membranes. 2014;4(3):424–46. https://doi.org/10.3390/membranes4030424.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  4. Cancer Genome Atlas Research N. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014;507(7492):315–22. https://doi.org/10.1038/nature12965.

    CAS  Article  Google Scholar 

  5. Das D, Xie L, Wang J, Xu X, Zhang Z, Shi J, et al. Discovery of new quinazoline derivatives as irreversible dual EGFR/HER2 inhibitors and their anticancer activities-part 1. Bioorg Med Chem Lett. 2019;29(4):591–6. https://doi.org/10.1016/j.bmcl.2018.12.056.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  6. De Pauw I, Lardon F, Van den Bossche J, Baysal H, Fransen E, Deschoolmeester V, et al. Simultaneous targeting of EGFR, HER2, and HER4 by afatinib overcomes intrinsic and acquired cetuximab resistance in head and neck squamous cell carcinoma cell lines. Mol Oncol. 2018;12(6):830–54. https://doi.org/10.1002/1878-0261.12197.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  7. Esparis-Ogando A, Montero JC, Arribas J, Ocana A, Pandiella A. Targeting the EGF/HER ligand-receptor system in cancer. Curr Pharm Des. 2016;22(39):5887–98.

    CAS  Article  PubMed Central  Google Scholar 

  8. Jeong J, Kim W, Kim LK, VanHouten J, Wysolmerski JJ. HER2 signaling regulates HER2 localization and membrane retention. PLoS One. 2017;12(4):e0174849. https://doi.org/10.1371/journal.pone.0174849.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  9. Khanjani F, Sajedi RH, Hasannia S. Rapid screening of drug candidates against EGFR/HER2 signaling pathway using fluorescence assay. Anal Bioanal Chem. 2018;410(30):7827–35. https://doi.org/10.1007/s00216-018-1403-1.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  10. Kriegmair MC, Wirtz RM, Worst TS, Breyer J, Ritter M, Keck B, et al. Prognostic value of molecular breast cancer subtypes based on Her2, ESR1, PGR and Ki67 mRNA-expression in muscle invasive bladder cancer. Transl Oncol. 2018;11(2):467–76. https://doi.org/10.1016/j.tranon.2018.02.001.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  11. Liao JB, Lee HP, Fu HT, Lee HS. Assessment of EGFR and ERBB2 (HER2) in gastric and gastroesophageal carcinomas: EGFR amplification is associated with a worse prognosis in early stage and well to moderately differentiated carcinoma. Appl Immunohistochem Mol Morphol. 2018;26(6):374–82. https://doi.org/10.1097/PAI.0000000000000437.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  12. Najy AJ, Day KC, Day ML. The ectodomain shedding of E-cadherin by ADAM15 supports ErbB receptor activation. J Biol Chem. 2008;283(26):18393–401. https://doi.org/10.1074/jbc.M801329200.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  13. Patil PU, D’Ambrosio J, Inge LJ, Mason RW, Rajasekaran AK. Carcinoma cells induce lumen filling and EMT in epithelial cells through soluble E-cadherin-mediated activation of EGFR. J Cell Sci. 2015;128(23):4366–79. https://doi.org/10.1242/jcs.173518.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  14. Robichaux JP, Elamin YY, Tan Z, Carter BW, Zhang S, Liu S, et al. Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer. Nat Med. 2018;24(5):638–46. https://doi.org/10.1038/s41591-018-0007-9.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  15. Roskoski R Jr. The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res. 2014;79:34–74. https://doi.org/10.1016/j.phrs.2013.11.002.

    CAS  Article  PubMed  Google Scholar 

  16. Rotterud R, Nesland JM, Berner A, Fossa SD. Expression of the epidermal growth factor receptor family in normal and malignant urothelium. BJU Int. 2005;95(9):1344–50. https://doi.org/10.1111/j.1464-410X.2005.05497.x.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  17. Sanguedolce F, Russo D, Mancini V, Selvaggio O, Calo B, Carrieri G, et al. Prognostic and therapeutic role of HER2 expression in micropapillary carcinoma of the bladder. Mol Clin Oncol. 2019;10(2):205–13. https://doi.org/10.3892/mco.2018.1786.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  18. Sharma B, Kanwar SS. Phosphatidylserine: A cancer cell targeting biomarker. Semin Cancer Biol. 2018;52(Pt 1):17–25. https://doi.org/10.1016/j.semcancer.2017.08.012.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  19. Steuer CE, Griffith CC, Nannapaneni S, Patel MR, Liu Y, Magliocca KR, et al. A correlative analysis of PD-L1, PD-1, PD-L2, EGFR, HER2, and HER3 expression in oropharyngeal squamous cell carcinoma. Mol Cancer Ther. 2018;17(3):710–6. https://doi.org/10.1158/1535-7163.MCT-17-0504.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  20. Su CC, Lu JL, Tsai KY, Lian IB. Reduction in arsenic intake from water has different impacts on lung cancer and bladder cancer in an arseniasis endemic area in Taiwan. Cancer Causes Control. 2011;22(1):101–8. https://doi.org/10.1007/s10552-010-9679-2.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Wichmann H, Guttler A, Bache M, Taubert H, Rot S, Kessler J, et al. Targeting of EGFR and HER2 with therapeutic antibodies and siRNA: a comparative study in glioblastoma cells. Strahlenther Onkol. 2015;191(2):180–91. https://doi.org/10.1007/s00066-014-0743-9.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Xue L, Maihle NJ, Yu X, Tang SC, Liu HY. Synergistic targeting HER2 and EGFR with bivalent aptamer-siRNA chimera efficiently inhibits HER2-positive tumor growth. Mol Pharm. 2018;15(11):4801–13. https://doi.org/10.1021/acs.molpharmaceut.8b00388.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  23. Yu X, Ghamande S, Liu H, Xue L, Zhao S, Tan W, et al. Targeting EGFR/HER2/HER3 with a three-in-one aptamer-siRNA chimera confers superior activity against HER2(+) breast cancer. Mol Ther Nucleic Acids. 2018;10:317–30. https://doi.org/10.1016/j.omtn.2017.12.015.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  24. Zhang Y, Zhang J, Liu C, Du S, Feng L, Luan X, et al. Neratinib induces ErbB2 ubiquitylation and endocytic degradation via HSP90 dissociation in breast cancer cells. Cancer Lett. 2016;382(2):176–85. https://doi.org/10.1016/j.canlet.2016.08.026.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  25. Zhou Q, Jin P, Liu J, Wang F, Xi S. HER2 and Src co-regulate proliferation, migration and transformation by downstream signaling pathways in arsenite-treated human uroepithelial cells. Metallomics. 2018;10(8):1141–59. https://doi.org/10.1039/c8mt00131f.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

Download references

Funding

This work was supported by the National Natural Science Foundation of China (NSFC) (81673207 and 81373023) and the Program for Liaoning Innovative Research Team in University (LNIRT) (201610159000037).

Author information

Affiliations

Authors

Corresponding author

Correspondence to Shuhua Xi.

Ethics declarations

Conflict of interests

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

ESM 1

(DOCX 10452 kb).

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Jin, P., Liu, J., Zhou, Q. et al. Long-term treatment with arsenite activates HER1 and HER2 through upregulating EGF, TGFα, and HSP90 in a human uroepithelial cell line. Cell Biol Toxicol 36, 279–284 (2020). https://doi.org/10.1007/s10565-019-09500-9

Download citation

Keywords

  • Arsenite
  • Cell proliferation
  • Urothelium
  • Human Epidermal Growth Factor Receptor